ISR Immune System Regulation Holding AB (publ) announced that ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive ART with the addition of GnRH agonist (ISR048), or ART alone. The first patient is now enrolled. ISR's Phase IIa clinical study, ISR-003, is conducted at the Karolinska University Hospital Huddinge and at the South Hospital in Stockholm, SÖS. The study is composed of two arms with a total of 26+26 patients to be randomized into ART+ISR048 or to ART alone in the control group. Patients will be treated for 3 months and then followed for an additional 3 months with the major readout HIV DNA reservoirs. The study is expected to be ending in second quarter of 2019.